Aft banks on stronger second half as strike and destocking hit first-half result

Aft banks on stronger second half as strike and destocking hit first-half result
Hartley Atkinson says Aft should have a new licensing deal for its Maxigesic pain relief soon. (Image: Aft Pharmaceuticals)
Rebecca Stevenson
Aft Pharmaceuticals is pinning its hopes on a stronger second-half result after a $2.46 million loss for the six months to Sept 30. The New Zealand Exchange (NZX) listed pharmaceutical manufacturer said its result was affected by a doctor strike in South Korea and several large customers reducing stock. These caused a $6.5m hit to product sales and royalties in Aft’s Asian and other international markets, the company said.Sales of its Maxigesic intravenous line were significantly affected by the now-resolved doctors' strike....

More Markets

James Miller to join Fletcher Building board
Infrastructure

James Miller to join Fletcher Building board

Miller is chair of Channel Infrastructure and will need to juggle some directorships.

Ryman's model is shaking up Oz retirement sector
Property

Ryman's model is shaking up Oz retirement sector

“It's a NZ innovation that Australians can't steal," says Ryman's COO. 

NZ sharemarket ends week up nearly 1.2%
Markets Market close

NZ sharemarket ends week up nearly 1.2%

The S&P/NZX 50 Index closed at 12,904.11, up 149.96 points or 1.18%.

Graham Skellern 20 Dec 2024
Marlborough Wine Estates' NZX delisting gets green light
Markets

Marlborough Wine Estates' NZX delisting gets green light

Cost savings were behind the decision to delist, the company says.

John Anthony 20 Dec 2024